Roberto Angioli
Experienced in Neuroendocrine Carcinoma of the Cervix

Roberto Angioli

Via Alvaro Del Portillo, 21, 
Rome, IT 
Experienced in Neuroendocrine Carcinoma of the Cervix
Via Alvaro Del Portillo, 21, 
Rome, IT 
OverviewLocationsClinical Research

Overview

Roberto Angioli practices in Rome, Italy. Mr. Angioli is rated as an Experienced expert by MediFind in the treatment of Neuroendocrine Carcinoma of the Cervix. His top areas of expertise are Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Hysterectomy, and Lymphadenectomy.

His clinical research consists of co-authoring 186 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Neuroendocrine Carcinoma of the Cervix.

Gender
Male

Locations

Via Alvaro Del Portillo, 21, Rome, 00128, Italy
Other Locations
Via Alvaro Del Portillo, Via, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

186 Total Publications

The Role of Deep Neuromuscular Blockade and Sugammadex in Laparoscopic Hysterectomy: A Randomized Controlled Trial.
The Role of Deep Neuromuscular Blockade and Sugammadex in Laparoscopic Hysterectomy: A Randomized Controlled Trial.
Journal: Journal of clinical medicine
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Angioli's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile